Literature DB >> 21319154

Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone.

Phoebe Holmes1, Joshua Lloyd, Inna Chervoneva, Edward Pequinot, Dennis B Cornfield, Gordon F Schwartz, Kathleen G Allen, Juan P Palazzo.   

Abstract

BACKGROUND: Increased use of breast cancer screening has led to an increase in the number of diagnosed cases of ductal carcinoma in situ (DCIS). However, there is no definite way to predict progression or recurrence of DCIS. We analyzed the significance of biological markers and tumor characteristics in predicting recurrence in a large series of DCIS patients with long-term follow-up treated with breast conservation surgery (BCS) alone.
METHODS: Clinical and pathological data were analyzed for 141 patients who underwent BCS for DCIS. All had negative surgical margins. Using local disease recurrence as an endpoint, we sought to determine the prognostic significance of several histopathological characteristics (tumor size, presence of necrosis, and subtype) and biological markers (estrogen receptor, progesterone receptor, and Her-2/neu.)
RESULTS: At a median follow-up of 122 months (maximum follow-up, 294 months), 60 recurrences occurred, with a median time to recurrence of 191 months. On multivariate analysis, Her-2 positivity (3+) was found to be significantly associated with reduced time to tumor recurrence (P = .028). Tumor size and higher grade were marginally statistically significant (P = .099, P = .070). Neither necrosis nor tumor pathological characteristics were found to be significantly related to time to disease recurrence.
CONCLUSIONS: Our results suggested that status of Her-2/neu, larger tumor size, and higher nuclear grade were significantly correlated with time to tumor recurrence in patients treated with BCS alone. Using logistical analyses, no significant correlation was found between tumor pathological characteristics and disease recurrence.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21319154     DOI: 10.1002/cncr.25942

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

Review 1.  Ductal carcinoma in situ of breast: update 2019.

Authors:  Sunil S Badve; Yesim Gökmen-Polar
Journal:  Pathology       Date:  2019-08-28       Impact factor: 5.306

2.  Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.

Authors:  Kathleen Lambein; Mieke Van Bockstal; Lies Vandemaele; Rudy Van den Broecke; Veronique Cocquyt; Sofie Geenen; Hannelore Denys; Louis Libbrecht
Journal:  Virchows Arch       Date:  2017-05-31       Impact factor: 4.064

3.  Clinicopathological variables predicting HER-2 gene status in immunohistochemistry-equivocal (2+) invasive breast cancer.

Authors:  Yongling Ji; Liming Sheng; Xianghui Du; Guoqin Qiu; Bo Chen; Xiaojia Wang
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

4.  Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype.

Authors:  Mieke Van Bockstal; Kathleen Lambein; Hannelore Denys; Geert Braems; Ann Nuyts; Rudy Van den Broecke; Veronique Cocquyt; Olivier De Wever; Louis Libbrecht
Journal:  Virchows Arch       Date:  2014-06-29       Impact factor: 4.064

5.  Mammographic features of calcifications in DCIS: correlation with oestrogen receptor and human epidermal growth factor receptor 2 status.

Authors:  Min Sun Bae; Woo Kyung Moon; Jung Min Chang; Nariya Cho; So Yeon Park; Jae-Kyung Won; Yoon-Kyung Jeon; Hyeong-Gon Moon; Wonshik Han; In Ae Park
Journal:  Eur Radiol       Date:  2013-03-20       Impact factor: 5.315

Review 6.  Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.

Authors:  Kevin Shee; Kristen E Muller; Jonathan Marotti; Todd W Miller; Wendy A Wells; Gregory J Tsongalis
Journal:  Am J Pathol       Date:  2018-10-29       Impact factor: 4.307

7.  Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial.

Authors:  Mangesh A Thorat; Pauline M Levey; J Louise Jones; Sarah E Pinder; Nigel J Bundred; Ian S Fentiman; Jack Cuzick
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531

Review 8.  DNA methylation in ductal carcinoma in situ of the breast.

Authors:  Jia-Min B Pang; Alexander Dobrovic; Stephen B Fox
Journal:  Breast Cancer Res       Date:  2013-06-28       Impact factor: 6.466

9.  Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review.

Authors:  Sara A Lari; Henry M Kuerer
Journal:  J Cancer       Date:  2011-05-01       Impact factor: 4.207

10.  Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis.

Authors:  Kirsty E Stuart; Nehmat Houssami; Richard Taylor; Andrew Hayen; John Boyages
Journal:  BMC Cancer       Date:  2015-11-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.